MCID: CHL018
MIFTS: 47

Childhood Medulloblastoma malady

Categories: Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Childhood Medulloblastoma

Aliases & Descriptions for Childhood Medulloblastoma:

Name: Childhood Medulloblastoma 12 50 14
Medulloblastoma, Childhood 50 69
Pediatric Medulloblastoma 12
Medulloblastoma Childhood 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3869
MeSH 42 D008527
NCIt 47 C3997
UMLS 69 C0278510

Summaries for Childhood Medulloblastoma

MalaCards based summary : Childhood Medulloblastoma, also known as medulloblastoma, childhood, is related to medulloblastoma and bone giant cell tumor, and has symptoms including headache, vomiting and gait ataxia. An important gene associated with Childhood Medulloblastoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Pathways in cancer and Wnt Signaling Pathways: beta-Catenin-independent Wnt/Ca2+ Signaling and Other Non-canonical Wnt Signaling Pathways. The drugs Cisplatin and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include bone, thyroid and brain, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Childhood Medulloblastoma

Graphical network of the top 20 diseases related to Childhood Medulloblastoma:



Diseases related to Childhood Medulloblastoma

Symptoms & Phenotypes for Childhood Medulloblastoma

UMLS symptoms related to Childhood Medulloblastoma:


headache, vomiting, gait ataxia

MGI Mouse Phenotypes related to Childhood Medulloblastoma:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 ERBB3 ERBB4 GLI2 MYC MYCN NTRK3
2 cardiovascular system MP:0005385 10.15 ERBB3 ERBB4 MYC MYCN NTRK3 PTCH1
3 growth/size/body region MP:0005378 10.15 DDX3X ERBB3 GLI2 MYC MYCN NTRK3
4 mortality/aging MP:0010768 10.13 GLI2 MYC MYCN NTRK3 PTCH1 SH3GL1
5 embryo MP:0005380 10.11 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
6 nervous system MP:0003631 10.11 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
7 craniofacial MP:0005382 10.01 ERBB4 GLI2 MYC MYCN PTCH1 SUFU
8 digestive/alimentary MP:0005381 10 ERBB3 GLI2 MYC MYCN PTCH1 SUFU
9 normal MP:0002873 9.96 SH3GL1 SUFU DDX3X ERBB3 ERBB4 GLI2
10 integument MP:0010771 9.95 ERBB3 ERBB4 GLI2 MYC PTCH1 SUFU
11 muscle MP:0005369 9.95 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
12 limbs/digits/tail MP:0005371 9.85 GLI2 MYC MYCN PTCH1 SUFU
13 no phenotypic analysis MP:0003012 9.8 GLI2 MYC MYCN NTRK3 PTCH1 SUFU
14 respiratory system MP:0005388 9.56 ERBB3 ERBB4 GLI2 MYCN NTRK3 PTCH1
15 pigmentation MP:0001186 9.46 ERBB3 MYC PTCH1 SUFU
16 vision/eye MP:0005391 9.1 GLI2 MYCN NTRK3 PRDM13 PTCH1 SUFU

Drugs & Therapeutics for Childhood Medulloblastoma

Drugs for Childhood Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
7
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
8
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
9
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
10
Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
11
Succinylcholine Approved Phase 3,Phase 2 306-40-1 5314
12
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
13
Mesna Approved Phase 3,Phase 2,Phase 1 3375-50-6 598
14 Sodium thiosulfate Approved Phase 3,Phase 1,Phase 2
15
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
16
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
17
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
19
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
20
Ondansetron Approved Phase 3 99614-02-5 4595
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
22
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
23 Alkylating Agents Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
27 Antimetabolites Phase 3,Phase 2
28 Antimetabolites, Antineoplastic Phase 3,Phase 2
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Dermatologic Agents Phase 3,Phase 2,Phase 1
31 Etoposide phosphate Phase 3,Phase 2,Phase 1
32 Folic Acid Antagonists Phase 3,Phase 2
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
34 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
35 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
36 Vitamin B Complex Phase 3,Phase 2
37 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
38 Protective Agents Phase 3,Phase 2,Phase 1
39 Liver Extracts Phase 3,Phase 2,Phase 1
40 Neuromuscular Agents Phase 3,Phase 2
41 Neuromuscular Blocking Agents Phase 3,Phase 2
42 Neuromuscular Depolarizing Agents Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
44 Antidotes Phase 3,Phase 2,Phase 1
45 Calcium, Dietary Phase 3,Phase 2
46 Micronutrients Phase 3,Phase 2
47 Trace Elements Phase 3,Phase 2
48 Vitamins Phase 3
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
50 Anti-Infective Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 137)
id Name Status NCT ID Phase
1 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3
2 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
3 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed NCT00085735 Phase 3
4 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed NCT00336024 Phase 3
5 Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor Completed NCT00006461 Phase 3
6 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Completed NCT00002875 Phase 3
7 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
8 Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma Recruiting NCT00392327 Phase 3
9 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3
10 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
11 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
12 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
13 Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery Unknown status NCT00276666 Phase 2
14 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2
15 High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood Unknown status NCT00180791 Phase 2
16 Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Completed NCT01239316 Phase 2
17 Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma Completed NCT02017964 Phase 2
18 Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma Completed NCT00003573 Phase 2
19 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Completed NCT00003211 Phase 2
20 Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors Completed NCT00025077 Phase 2
21 Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors Completed NCT00002594 Phase 2
22 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2
23 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2
24 Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors Completed NCT00003203 Phase 2
25 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2
26 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2
27 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2
28 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2
29 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2
30 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2
31 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Completed NCT00005811 Phase 2
32 Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors Completed NCT00003846 Phase 2
33 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2
34 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2
35 Lobradimil and Carboplatin in Treating Children With Brain Tumors Completed NCT00019422 Phase 2
36 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
37 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
38 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2
39 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2
40 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2
41 Docetaxel in Treating Children With Recurrent Solid Tumors Completed NCT00002825 Phase 2
42 Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00003241 Phase 2
43 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2
44 Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Recruiting NCT02684071 Phase 2
45 WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Recruiting NCT02095132 Phase 1, Phase 2
46 Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Recruiting NCT02624388 Phase 2
47 A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Recruiting NCT01878617 Phase 2
48 Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors Recruiting NCT00983398 Phase 1, Phase 2
49 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Active, not recruiting NCT01217437 Phase 2
50 Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma Active, not recruiting NCT00105560 Phase 2

Search NIH Clinical Center for Childhood Medulloblastoma

Genetic Tests for Childhood Medulloblastoma

Anatomical Context for Childhood Medulloblastoma

MalaCards organs/tissues related to Childhood Medulloblastoma:

39
Bone, Thyroid, Brain, Testes, Parietal Lobe

Publications for Childhood Medulloblastoma

Articles related to Childhood Medulloblastoma:

(show top 50) (show all 126)
id Title Authors Year
1
Evolving molecular era of childhood medulloblastoma: time to revisit therapy. ( 26617331 )
2016
2
Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ( 27900530 )
2016
3
Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns. ( 27770281 )
2016
4
The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ( 27785591 )
2016
5
Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. ( 28039368 )
2016
6
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. ( 27040285 )
2016
7
Childhood medulloblastoma. ( 27375228 )
2016
8
Evidence of high mortality in long term survivors of childhood medulloblastoma. ( 25557108 )
2015
9
The use of 5-ALA to assist complete removal of residual non-enhancing part of childhood medulloblastoma: a case report. ( 26070965 )
2015
10
CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma. ( 26290144 )
2015
11
The biologic era of childhood medulloblastoma and clues to novel therapies. ( 24754593 )
2014
12
Germline Mutations in SUFU Cause Gorlin Syndrome-Associated Childhood Medulloblastoma and Redefine the Risk Associated With PTCH1 Mutations. ( 25403219 )
2014
13
Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature. ( 24276042 )
2014
14
NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. ( 24708907 )
2014
15
Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. ( 25346052 )
2014
16
Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. ( 24569911 )
2014
17
miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. ( 23970061 )
2013
18
Treatment options for childhood medulloblastoma. ( 24069828 )
2013
19
A contemporary review of molecular candidates for the development and treatment of childhood medulloblastoma. ( 23292496 )
2013
20
Identification of suitable endogenous control genes for microRNA expression profiling of childhood medulloblastoma and human neural stem cells. ( 22980291 )
2012
21
Cerebral white matter integrity and executive function in adult survivors of childhood medulloblastoma. ( 23095827 )
2012
22
Low-grade bone lesions in survivors of childhood medulloblastoma/primitive neuroectodermal tumor. ( 22054800 )
2012
23
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. ( 22153558 )
2012
24
Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. ( 22994552 )
2012
25
Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma. ( 22350379 )
2012
26
Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile. ( 22826514 )
2012
27
Chemotherapy dose-intensity and survival for childhood medulloblastoma. ( 22993333 )
2012
28
An exploratory case-only analysis of gene-hazardous air pollutant interactions and the risk of childhood medulloblastoma. ( 22389292 )
2012
29
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. ( 22139329 )
2012
30
Risk-adapted chemotherapy in childhood medulloblastoma. ( 21554052 )
2011
31
Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. ( 21367970 )
2011
32
Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. ( 20931205 )
2011
33
Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells. ( 21931624 )
2011
34
Recurrence in childhood medulloblastoma. ( 21069427 )
2011
35
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. ( 20921458 )
2011
36
Childhood medulloblastoma. ( 21129995 )
2011
37
Expression of Oa8P-methylguanine-DNA methyltransferase in childhood medulloblastoma. ( 20820873 )
2011
38
Early traits of metabolic syndrome in pediatric post-cancer survivors: outcomes in adolescents and young adults treated for childhood medulloblastoma. ( 22218450 )
2011
39
Intact language skills and semantic processing speed following the use of fractionated cranial irradiation therapy for the treatment of childhood medulloblastoma: a 4-year follow-up study. ( 21207315 )
2011
40
Progress in sequencing human cancer genomes: advancements in childhood medulloblastoma. ( 21900800 )
2011
41
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. ( 20845476 )
2011
42
Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. ( 21317922 )
2011
43
Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. ( 20652577 )
2010
44
Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD. ( 20053783 )
2010
45
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. ( 20978505 )
2010
46
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. ( 20940197 )
2010
47
A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma. ( 19806481 )
2010
48
Childhood medulloblastoma: current status of biology and treatment. ( 20297854 )
2010
49
RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. ( 19134217 )
2009
50
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone-a critical review. ( 20689605 )
2009

Variations for Childhood Medulloblastoma

Expression for Childhood Medulloblastoma

Search GEO for disease gene expression data for Childhood Medulloblastoma.

Pathways for Childhood Medulloblastoma

GO Terms for Childhood Medulloblastoma

Cellular components related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ciliary base GO:0097546 8.96 GLI2 SUFU
2 receptor complex GO:0043235 8.8 ERBB3 ERBB4 NTRK3

Biological processes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.91 DDX3X ERBB4 GLI2 MYC
2 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.89 GLI2 MYC PRDM13 PTCH1 SUFU
3 positive regulation of transcription, DNA-templated GO:0045893 9.83 ERBB4 GLI2 MYC MYCN PTCH1
4 in utero embryonic development GO:0001701 9.81 GLI2 MYC PTCH1
5 peptidyl-tyrosine phosphorylation GO:0018108 9.77 ERBB3 ERBB4 NTRK3
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.73 ERBB3 ERBB4 NTRK3
7 heart development GO:0007507 9.67 ERBB3 ERBB4 GLI2 NTRK3
8 positive regulation of cell proliferation GO:0008284 9.65 ERBB4 GLI2 MYC MYCN NTRK3
9 negative regulation of osteoblast differentiation GO:0045668 9.64 PTCH1 SUFU
10 ERBB2 signaling pathway GO:0038128 9.64 ERBB3 ERBB4
11 mammary gland development GO:0030879 9.63 GLI2 PTCH1
12 regulation of cell motility GO:2000145 9.62 ERBB3 ERBB4
13 branching morphogenesis of an epithelial tube GO:0048754 9.62 GLI2 MYCN
14 positive regulation of mesenchymal cell proliferation GO:0002053 9.61 MYC MYCN
15 regulation of smoothened signaling pathway GO:0008589 9.59 GLI2 PTCH1
16 spinal cord motor neuron differentiation GO:0021522 9.58 GLI2 PTCH1
17 negative regulation of smoothened signaling pathway GO:0045879 9.57 PTCH1 SUFU
18 negative regulation of ERBB signaling pathway GO:1901185 9.55 ERBB3 ERBB4
19 mammary gland epithelial cell differentiation GO:0060644 9.54 ERBB4 PTCH1
20 dorsal/ventral neural tube patterning GO:0021904 9.52 GLI2 PTCH1
21 negative regulation of astrocyte differentiation GO:0048712 9.51 MYCN NTRK3
22 negative regulation of cell division GO:0051782 9.48 MYC PTCH1
23 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.46 GLI2 PTCH1
24 mammary gland duct morphogenesis GO:0060603 9.4 GLI2 PTCH1
25 spinal cord dorsal/ventral patterning GO:0021513 9.32 GLI2 SUFU
26 smoothened signaling pathway involved in ventral spinal cord interneuron specification GO:0021775 9.16 GLI2 SUFU
27 positive regulation of gene expression GO:0010628 9.02 DDX3X ERBB3 MYC MYCN NTRK3
28 smoothened signaling pathway involved in spinal cord motor neuron cell fate specification GO:0021776 8.96 GLI2 SUFU
29 regulation of transcription, DNA-templated GO:0006355 10.13 DDX3X ERBB4 GLI2 MYC MYCN PRDM13

Molecular functions related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.33 ERBB3 ERBB4 NTRK3
2 transcription factor binding GO:0008134 9.26 DDX3X GLI2 MYC SUFU
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 ERBB3 ERBB4 NTRK3

Sources for Childhood Medulloblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....